|By ACN Newswire||
|July 14, 2014 02:53 AM EDT||
Partnership with Roche Pharma Research and Early Development leverages a unique discovery by A*STAR's Bioprocessing Technology Institute to develop new approaches for cancer detection and treatment
|Singapore, July 14 - BTI's mAbs have a novel mechanism of action; causing membrane damage to cancer cells that result in cell death. The image on the left shows untreated cancer cells, while the image on the right depicts antibody-treated cancer cells with lesions and pores on the cell surface|
The collaboration makes use of BTI's discovery of a new mechanism where antibodies can directly target and destroy cancer cells, which has the potential for an entirely new class of cancer treatment. Cancer cells may be distinguished from normal cells by their elevated levels of sugar on the cell surface. The mAbs discovered and generated by BTI are able to recognise these sugar targets and allow more accurate identification of cancer cells as compared to traditional antibodies that only target proteins. mAbs generated by BTI are also unique in having a novel mechanism of action; they cause pores to form on the surface of cancer cells, leading to cell degradation and the eventual death of these diseased cells.
Dr Andre Choo, Principal Scientist at BTI and lead investigator for the project, said, "It is exciting to be able to generate a new class of mAbs that can specifically recognise sugars and lead to rapid death of diseased cells. This opens up new strategies to target and kill cancer cells."
Based on this discovery, scientists from BTI have developed a pipeline of mAbs for major cancers found in Singapore. The partnership with Roche will allow new diagnostic tests and cancer treatments to be developed more quickly and to be brought earlier to patient care. Such treatments could complement and augment existing cancer drugs and result in more effective and safer treatments for cancer patients.
Prof Lam Kong Peng, Executive Director of BTI, said, "This collaboration underscores the effectiveness of BTI's antibody research and allows us to leverage on Roche's expertise to develop novel antibody-based therapeutics. We are confident that this will be the start of a long and fruitful partnership that will not only benefit human health but also the biologics industry."
Dr. Juan-Carlos Lopez, Head of the Roche Pharma Research and Early Development Academic Relations and Collaborations, said: "Accessing external innovation through partnerships with public sector research institutes is crucial for identifying first-in-class or best-in-class opportunities. Bringing together the know-how of BTI and the expertise of Roche increases the chance of success in developing novel antibody-based therapeutics targeting both cancer and cancer stem cells which have the potential to revolutionize how we treat cancer."
Please see the full press release at http://bit.ly/1qXiA9S
Bioprocessing Technology Institute (BTI) is a member of the Agency for Science, Technology and Research (A*STAR). Established in 1990 as the Bioprocessing Technology Unit, it was renamed the Bioprocessing Technology Institute (BTI) in 2003. The research institute's mission is to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocessing community. Some of the key research areas include expression engineering, animal cell technology, stem cell research, microbial fermentation, downstream purification and analytics. For more information about BTI, please visit http://bti.a-star.edu.sg.
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that fosters world-class scientific research and talent to drive economic growth and transform Singapore into a vibrant knowledge-based and innovation driven economy.
In line with its mission-oriented mandate, A*STAR spearheads research and development in fields that are essential to growing Singapore's manufacturing sector and catalysing new growth industries. A*STAR supports these economic clusters by providing intellectual, human and industrial capital to its partners in industry.
A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities, located in Biopolis and Fusionopolis, as well as their vicinity. These two R&D hubs house a bustling and diverse community of local and international research scientists and engineers from A*STAR's research entities as well as a growing number of corporate laboratories. For more information on A*STAR, please visit www.a-star.edu.sg.
Ms Vanessa Loh Senior Officer, Corporate Communications Agency for Science, Technology and Research (A*STAR) Tel: +65 6826 6395 Email: [email protected]
Copyright 2014 ACN Newswire. All rights reserved.
Oct. 28, 2016 05:45 PM EDT Reads: 1,723
Oct. 28, 2016 05:30 PM EDT Reads: 289
Oct. 28, 2016 05:30 PM EDT Reads: 3,321
Oct. 28, 2016 04:45 PM EDT Reads: 301
Oct. 28, 2016 04:30 PM EDT Reads: 1,227
Oct. 28, 2016 04:30 PM EDT Reads: 772
Oct. 28, 2016 04:30 PM EDT Reads: 5,254
Oct. 28, 2016 04:00 PM EDT Reads: 3,876
Oct. 28, 2016 03:15 PM EDT Reads: 1,382
Oct. 28, 2016 03:00 PM EDT Reads: 433
Oct. 28, 2016 02:30 PM EDT Reads: 1,250
Oct. 28, 2016 02:15 PM EDT Reads: 1,021
Oct. 28, 2016 02:15 PM EDT Reads: 4,025
Oct. 28, 2016 02:00 PM EDT Reads: 2,955
SYS-CON Events announced today that eCube Systems, the leading provider of modern development tools and best practices for Continuous Integration on OpenVMS, will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. eCube Systems offers a family of middleware products and development tools that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
Oct. 28, 2016 02:00 PM EDT Reads: 4,703